We, the undersigned, hereby petition for the legalization of Generic Adderall in India for medical purposes.

Reasons for Legalization:

• Ineffective Alternatives: Many patients suffering from conditions like Attention Deficit Hyperactivity Disorder (ADHD), narcolepsy, and other disorders find that existing medications do not provide adequate relief. Amphetamines have demonstrated effectiveness in managing these conditions, enhancing focus, attention, and overall quality of life.
• Global Precedent: Numerous countries, including the United States, Canada, and several European nations, have recognized the medical benefits of amphetamines. These countries have implemented regulated frameworks allowing for safe prescription and use. By adopting a similar approach, India can better address the needs of patients requiring effective treatment.
• Economic Benefits: Legalizing amphetamines could lead to the creation of a regulated market, offering economic benefits through taxation and reducing illegal drug trafficking. This would also facilitate the establishment of proper medical protocols and training for healthcare providers.
• Patient Choice and Autonomy: Patients should have the right to explore all available treatment options with their healthcare providers. Legalization would empower patients to make informed decisions about their care, ensuring they receive the most effective treatment tailored to their individual needs.
• Addressing Stigma: Legalizing amphetamines for medical use can help reduce the stigma associated with their use, fostering better understanding and acceptance of these medications among healthcare professionals and the general public.

Conclusion:

We urge the government to take this petition seriously and act swiftly to legalize amphetamines for medical use in India. Many people, like myself, are suffering and require effective treatment options to manage our conditions. By taking this step, the government can provide relief and support to countless individuals in need.

Sincerely,

Raees 

26/10/24